TABLE 1.
Baseline characteristics (n = 327)
| Characteristics | Category |
Infection post‐ICI (n = 89) |
No infection post‐ICI (n = 238) |
p‐value |
|---|---|---|---|---|
| Age | Median (range) | 69 (24‐94) | 66 (26‐93) | 0.07 |
| Gender | Male | 57 (64%) | 138 (58%) | 0.38 |
| Female | 32 (37%) | 100 (42%) | ||
| Tumor type | Melanoma (cutaneous) | 36 (40%) | 119 (50%) | 0.03 |
| Lung (non‐small cell) | 32 (36%) | 87 (37%) | ||
| Genitourinary | 14 (16%) | 15 (6%) | ||
| Gynecological | 3 (3%) | 1 (<1%) | ||
| Head and neck | 3 (3%) | 3 (1%) | ||
| Non‐cutaneous melanoma | 1 (1%) | 2 (1%) | ||
| Breast | 0 (0%) | 3 (1%) | ||
| Merkel cell carcinoma | 0 (0%) | 2 (1%) | ||
| Mesothelioma | 0 (0%) | 3 (1%) | ||
| Sarcoma | 0 (0%) | 3 (1%) | ||
| Treatment stage | Localized Disease | 4 (4%) | 16 (7%) | 0.61 |
| Metastatic Disease | 85 (96%) | 222 (93%) | ||
| Treatment type | Anti‐PD(L)1 | 74 (83%) | 179 (75%) | 0.48 |
| Anti‐CTLA4 | 5 (6%) | 23 (10%) | ||
| Anti‐PD(L)1 + antiCTLA4 | 10 (11%) | 36 (15%) | ||
| Treatment duration | Cycles received | 7 (1‐98) | 5 (1‐71) | 0.38 |
| Corticosteroid | Corticosteroid for immune‐related adverse events | 46 (52%) | 103 (43%) | 0.21 |
| Comorbidities | Diabetes | 6 (7%) | 29 (12%) | 0.23 |
| Charlson comorbidity index(9) ‐ median (range) | 9 (4‐14) | 9 (2‐15) | 0.09 |